Sunflower Pharmaceutical announced that the company decided to use its own capital of RMB 10 million to invest in the establishment of a wholly-owned subsidiary, Sichuan Sunflower Pharmaceutical Co., Ltd., and the company holds 100% of the shares. The investment aims to promote the division and independent operation of each business segment of the marketing system and improve overall operational efficiency. This matter does not constitute a related transaction or major asset restructuring, and is within the authority of the board of directors, there is no need to submit it to the shareholders' meeting for consideration.

Sunflower Pharmaceutical announced that the company decided to use its own capital of RMB 10 million to invest in the establishment of a wholly-owned subsidiary, Sichuan Sunflower Pharmaceutical Co., Ltd., and the company holds 100% of the shares. The investment aims to promote the division and independent operation of each business segment of the marketing system and improve overall operational efficiency. This matter does not constitute a related transaction or major asset restructuring, and is within the authority of the board of directors, there is no need to submit it to the shareholders' meeting for consideration.